Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Creating a Publication-Ready Data Package from Preclinical AAV Vector Analytics

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Creating a Publication-Ready Data Package from Preclinical AAV Vector Analytics

AAV Vector Analytics for Publication-Ready Data Packages

CELL & GENE | RNA | BIOLOGICS

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Generating a robust analytical data package for an AAV vector program requires a cohesive strategy that anticipates regulatory scrutiny. The process involves building a clear, defensible narrative from early process development through IND-enabling toxicology studies. This integrates vector characterization, potency, and purity data with a deep understanding of vector biology. The objective is to assemble a data package that meets GxP standards and provides a transparent, scientifically sound foundation for regulatory review, supporting an 18-24 month timeline to IND.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

Technical FAQ

    What are the core components of an IND-enabling AAV analytical package?

    A comprehensive package must quantify vector identity, purity, potency, and stability. Key assays include genomic and physical titer (qPCR/ddPCR, ELISA), capsid protein profiling (SDS-PAGE, CE-SDS), empty/full capsid ratio analysis (AUC, AEX-HPLC), and a qualified, product-specific potency assay. Residuals testing for host cell proteins, DNA, and process-related impurities is also standard under GxP conditions.

    How is data from non-clinical studies integrated with CMC analytics?

    Data from in vivo biodistribution and toxicology studies must be directly correlated with the specific vector lot used. The analytical characterization of that lot serves as the reference standard. This linkage demonstrates that the material tested non-clinically is representative of the material intended for clinical use, a key requirement for regulatory bodies.

    Why is understanding pre-existing AAV immunity important for the data package?

    Pre-existing neutralizing antibodies (NAbs) against AAV capsids can impact vector efficacy. Data packages must account for this variable through a well-defined immunogenicity risk assessment. This includes developing and qualifying appropriate assays to measure baseline immunity and potential responses to the vector, demonstrating a proactive approach to a known clinical variable.

A scientist in protective gear pipetting a sample into a vial within a sterile laboratory hood.

Building a Coherent Regulatory Narrative

The transition from research-grade vector production to a GxP-compliant manufacturing process requires a fundamental shift in documentation. Every analytical result, from plasmid sequence verification to final product release testing, becomes a building block in the Investigational Medicinal Product Dossier (IMPD) or IND submission. Fragmented data, generated without a clear line of sight to regulatory expectations, can introduce significant delays and queries during review.

Our approach focuses on creating this narrative from the outset by establishing phase-appropriate analytical controls and documentation practices early. This methodology is informed by the collective experience of our core scientific team, whose work has contributed to a 100% successful IND rate for supported programs since 2019. With the launch of Franklin Biolabs in 2024, this legacy of expertise now provides the foundation for our services, ensuring data generated for process development supports future regulatory filings.

Integrating Vector Biology and Analytical Data

An analytical data package is incomplete if it only presents chemistry results in a vacuum. It must also address the biological behavior of the vector. Understanding the nuances of immune responses to AAV is a significant part of de-risking a program. Longitudinal studies have shown that natural AAV exposure can induce broad, cross-serotype neutralizing antibody responses (PMID: 27314914).

This biological reality informs our analytical strategy for immunogenicity, shaping how we design assays and interpret data from IND-enabling studies. This level of insight ensures the data package proactively addresses potential questions about immunogenicity and its impact on the therapeutic’s profile. It requires strategic documentation systems accelerating audit readiness by design.

Our vector core operations are structured for rapid reagent delivery, supported by a collaborative project management approach. Logistical strategies are aligned with specific program requirements, including the consolidation of shipments to optimize timelines and reduce pass-through costs.

A scientist in a lab coat and gloves loads samples into a ProteinSimple instrument for analysis.

Technical Visualization: AAV Analytical Data Package Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities